MARKET

BBOT

BBOT

BridgeBio Oncology Therapeutics, Inc
NASDAQ
8.88
-0.35
-3.79%
After Hours: 8.99 +0.11 +1.24% 17:07 03/27 EDT
OPEN
9.23
PREV CLOSE
9.23
HIGH
9.36
LOW
8.86
VOLUME
143.75K
TURNOVER
--
52 WEEK HIGH
14.87
52 WEEK LOW
8.50
MARKET CAP
710.69M
P/E (TTM)
44.47
1D
5D
1M
3M
1Y
5Y
1D
BridgeBio Oncology Therapeutics files Form 3; director Peter F. Lebowitz reports no securities beneficially owned
Reuters · 1d ago
BridgeBio Oncology Therapeutics appoints Peter Lebowitz to board; board size increases to nine directors
Reuters · 1d ago
Weekly Report: what happened at BBOT last week (0316-0320)?
Weekly Report · 4d ago
BridgeBio Oncology Therapeutics to present research at AACR Annual Meeting 2026
Reuters · 03/18 20:07
BBOT ANNOUNCES MULTIPLE PRESENTATIONS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2026
Reuters · 03/18 20:05
Wedbush Remains a Buy on BridgeBio Oncology Therapeutics (BBOT)
TipRanks · 03/17 13:16
Weekly Report: what happened at BBOT last week (0309-0313)?
Weekly Report · 03/16 10:30
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) and Biohaven Ltd. (BHVN)
TipRanks · 03/10 11:20
More
About BBOT
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.

Webull offers BridgeBio Oncology Therapeutics Inc stock information, including NASDAQ: BBOT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBOT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBOT stock methods without spending real money on the virtual paper trading platform.